Market Overview

UPDATE: Canaccord Genuity Initiates Coverage on MiMedx Group on Potential of New Segment


In a report published Friday, Canaccord Genuity analyst William J. Plovanic initiated coverage on MiMedx Group (NASDAQ: MDXG) with a Buy rating and $6.00 price target.

In the report, Canaccord Genuity noted, “By our estimates, the dermal substitute segment of the advanced wound care market generated ~$354M of revenues in 2012, growing ~23% per year since 2009. MiMedx utilizes distinct distribution channels for its three revenue reporting segments: Wound Care, Surgical & Sports Medicine, and Other/OEM. We believe the increasing number of reps in the direct channel on the commercial side for wound care, combined with improved coverage, will drive top-line growth in 2013 and beyond. AWC Direct reps are expected to increase to ~140 by YE15 from ~49 in Q2/13.”

MiMedx Group closed on Thursday at $4.54.

Latest Ratings for MDXG

Feb 2018Lake StreetDowngradesBuyHold
Feb 2018NeedhamDowngradesStrong BuyHold
May 2017First AnalysisDowngradesEqual-WeightUnderweight

View More Analyst Ratings for MDXG
View the Latest Analyst Ratings


Related Articles (MDXG)

View Comments and Join the Discussion!

Posted-In: Canaccord Genuity William J. PlovanicAnalyst Color Initiation Analyst Ratings

Latest Ratings

SBNYWells FargoMaintains95.0
TMOWells FargoMaintains300.0
VFCWells FargoMaintains70.0
WATWells FargoMaintains180.0
DGXWells FargoMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at